These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21540307)

  • 1. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
    Leclercq S; Gueugnon F; Boutin B; Guillot F; Blanquart C; Rogel A; Padieu M; Pouliquen D; Fonteneau JF; Grégoire M
    Eur Respir J; 2011 Nov; 38(5):1105-16. PubMed ID: 21540307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
    Roulois D; Blanquart C; Panterne C; Gueugnon F; Grégoire M; Fonteneau JF
    Eur J Immunol; 2012 Mar; 42(3):783-9. PubMed ID: 22144115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
    Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
    Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth.
    Guillot F; Boutin B; Blanquart C; Fonteneau JF; Robard M; Grégoire M; Pouliquen D
    Vaccine; 2011 Jul; 29(33):5534-43. PubMed ID: 21619908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
    J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.
    Roulois D; Vignard V; Gueugnon F; Labarrière N; Grégoire M; Fonteneau JF
    Eur Respir J; 2011 Nov; 38(5):1117-26. PubMed ID: 21540305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
    Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
    Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
    Ebstein F; Sapede C; Royer PJ; Marcq M; Ligeza-Poisson C; Barbieux I; Cellerin L; Dabouis G; Grégoire M
    Am J Respir Crit Care Med; 2004 Jun; 169(12):1322-30. PubMed ID: 15070823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
    Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
    Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
    Opitz I; Sigrist B; Hillinger S; Lardinois D; Stahel R; Weder W; Hopkins-Donaldson S
    Lung Cancer; 2007 Jun; 56(3):327-36. PubMed ID: 17383050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
    Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
    Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
    Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
    Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
    Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
    Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
    Hegmans JP; Hemmes A; Hammad H; Boon L; Hoogsteden HC; Lambrecht BN
    Eur Respir J; 2006 Jun; 27(6):1086-95. PubMed ID: 16540497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
    Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
    J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
    Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
    Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.